Pasithea Therapeutics announced the invention of a crystalline form of PAS-004 which is captured in polymorph and stereoisomer patent filings that when issued we believe will extend patent protection to at least 2045.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KTTA:
- Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
- Pasithea Therapeutics announces FDA acceptance of IND application for PAS-004
- Pasithea Therapeutics Corp trading halted, news pending
- Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
- Pasithea Therapeutics Announces Results from 2023 Annual Meeting
